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BCG : DO WE HAVE AN ALTERNATIVE
Vaccination is generally used as a form of immunopro-
phylaxis, so that administration of the vaccine even a
long. time before exposure to the wild-type infectious
organism should afford protection. Since effector T
and B cells are short-lived, a prime requisite for a
vaccine is to generate immunological memory.1 In the
case organisms such as mycobacteria which are
obligate intracellular pathogens and which elicit
granulomatous tissue reactions, artificial immunisation
with live bacteria is required to induce protection.2,3
The only existing vaccine against tuberculosis is the
BCG (Bacille Calmette - Guerin), an attenuated strain
of M.bovis and it is mandatory or officially recom-
mended in 182 countries or territories.Under the
Expanded Programmeon Immuisation (EPT) started
by the Government of India in 1978, BCG is recom-
mended to be given to all infants 3-9 months after
birth.4
led t  the fortuitous observation that growth in the   
pres ce of bile also resulted in attenuation or gradual
loss of virulence.Such attenuated organisms will    
multiply only to a limited extent in the animal or human
body nd can bring about an increase in the resistance
of the host to a subsequent fully virulent infection by
the same or other antigenically closely related organ-
isms. Calmette further attenuated this strain by cul-
tivation of the organism on a potato-glycerol-bile medium
for 230 serial transfer! between the years 1908 and
1918.
History of BCG Vaccine
The history of BCG vaccination and the trials
conducted to assess its effectiveness in humans have
been reviewed by many workers.5-10 BCG, the bile-
tolerant, attenuated strain of M.bovis, was isolated by
Calmette and Guerin.11 Ox-bile was originally added
to these cultures to prevent clumping of bacilli. This
The bacilli resulting from this attentuation have
never been cloned. The original strain of BCG has been
lost and has been replaced by a variant while it was  
being transferred serially on artificial culture media at
the Pasteur Institute12 and have since been maintained
by many different laboratories, using many different
methods. As a result, the BCG strains used today are
not bacterioiogically identical.13,14 In 1966, a WHO
Expert Committee on Biological Standardisation adopted
a series of recommendations for the production of BCG
vaccine. 15 These recommendations stated that the vaccine
should be freeze-dried, and that the vaccine strain
should be maintained by theseed-lot-system whereby
no vaccine isproduced from a seed more than 12
p a s s a g e s  removedfrom a primary freeze-dried lot.
Such a method of maintenance was soon adopted by
most laboratories and this eliminated the possibility of
more attenuated variants in later BCG vaccine lots.16
BCG Vaccine Production in India
In India, the BCG Vaccine Laboratory was started
in Madras in 1948 for the production of BCG vaccine
for use in India and also for supply to some of the
neighbouring countries.Since 1966, Danish strain
1331 is being used here for the preparation of both the
liquid and the freezedried BCG vaccines, based on the
seed-lot-system17.
For preparing the liquid and freeze-dried vaccine.
the BCG Laboratory, Madras, uses the method followed
  at the State Serum Institute, Copenhagen, but using
Sauton potato medium for maintaining the BCG strain.
The prepared vaccine is tested for purity by Ziehl-
Neelsen smear for acid fast bacilli, and by culture on
nutrient broth, thioglycollate medium and Sabouraud’s
agar medium. Total bacterial count and the number
of culturable particles in the preparation are estimated.
Biological tests are carried out in guineapigs to estimate
the degree of virulence of the BCG vaccine, allergenicity
and safety. In addition to the above tests, in the case
of the freeze-dried vaccine, tests are carried out to
estimate residual. moisture and heat stability. Both
types of vaccines are to be stored at refrigeration
temperature, protected from light, Under these con-
ditions of storage, the liquid vaccine can be used for
4 weeks from the date of manufacture while the freeze-
dried vaccine can be used for 3 months.
BCG can be administered intracutaneously, orally,
by scarification or by multiple puncture. The most
widely used method of administration is by intracuta-
neous injection. The dose is usually 0.1 ml and the
site of injection is the upper arm. In the newborn, the
dose used is 0.05 ml. The liquid BCG vaccine prepared
by the BCG Laboratory, Madras, is to be administered
by an intracutaneous injection of 0.1 ml of the vaccine
containing 0.075 mg (moist weight) of BCG. The
freeze-dried vaccine prepared here is reconstituted by
the addition of sterile distilled water or sterile saline
to contain 0.1 mg (moist weight) in 0.1 ml of vaccine
which is given intracutaneously.
Efficacy of BCG Vaccine
BCG was used successfully in humans for the first
time in 1921 by Weil-Halle, a colleague of Calmette
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and Guerin. 18 Scepticism concerning the safety an;
fficacy of BCG vaccine, and the Lubeck disaster in
which 72 of 240 children vaccinated with BCG did
as a result of being fed a batch of vaccine containing
virulenttubercle bacilli, delayed the acceptance of
BCG. A series of controlled trials were begun in the
1930s. Despite inconsistent results from the trials,
WHO encouraged widespread dissemination of BCG
vaccines, starring in the 195Os. By the 1970s, BCG
became the most widely used vaccine in the world.
About 3 billion doses have been given in the last four
decades, and more than 70 per cent of the world’s
children now receive BCG.5,19
Table: Protective efficacy of BCG vaccine against tuber-
culosis
Population group Period of intake Protective
efficacy (%)
North American Indians1935-1938 80
Chicago infants 1937-1948 75
Georgia school children1947 None
Illinois children 1917-1948 None
Puerto Rico 1949-1951 31
gen ral population
Georgia and Alabama
general population
British children
South Indian
rural population
The South Indian Trial
A study was started in Chingleput, South India, in
1968 in an attempt to avoid the methodologic errors
that might have affected previous trials. 10,20,21 The south
IndianBCG trial was organised by the Indian Council
of Medical Research (ICMR) in collaboration with the
WHO and Centre for Disease Control (CDC), US
Public Health Services. The intake for the study started
in 1968 and was completed in 1971, including about
2.6 lakh participants out of a population of 3.6 lakhs.
The entire population of all ages was eligible and
tuberculin reactors were notexcluded, in  contrast  with
previous trials. Two BCG strains, Copenhagen andin those with intermediate levels of tuberculin reactiv-
Paris, were tested at two doses, 0.1 mg and 0.01 mg.ity, and this was thought to be due to non-tuberculosis
Neither of the vaccines, whether in full or reducedmy obacterial infection. in the Puerto Rico trial.
dosage, had given any protection against the bacillary
form of pulmonary tuberculosis as assessed over a 7.5
year follow up period. No data are available from the
study to evaluate protection in children. Very little
disease was observed in the period immediately after
infection.22 Incidence peaks were absent in young
children and in young adults but the incidence increased
logarithmically with age.
The findings of the south Indian trial were disappoint-
ing. The ICMR convened an expert committee meeting
to scrutinise the trial methodology, wherein it was
agreed that no errors in the conduct of the field op-
erations or in the data processing could have been so
serious as to invalidate the results.10 In the first meeting
of the ICMR/WHO Scientific Group23 it was stated that
the data obtained in this trial are unique and of great
importance for tropical countries. and should be con-
sidered as the starting, point for further intensive in-
vestigations into the epidemiological, bacteriological
and immunological problems related to BCG vaccine
and tuberculosis, as well as studies to test certain
hypotheses, eg, that the immune response of the popu-
lation was unusual, that the vaccine were inadequate
to confer immunity, that the south Indian variant of M.
tuberculosis acted as an attenuated immunising agent,
and that mycobacteria other than M. tuberculosis may
have partially immunised the study population.
Explanations for the Varying Efficacy of BCG
The explanations and hypotheses for the varying
efficacy of BCG have been discussed in detail. 5,7 BCG   
varying efficacy due to interactions with the immune
responses to other mycobacterial infections still re-
mains one of the most popular explanations. Palmer and
associates24,25 showed in animal experiments, and in
studies of US navy personnel, that infections with
certain non-tubercuious mycobacteria could impart some
protection against infection with the tubercle bacillus
and such naturally acquired protection could mask any
protection due to BCG vaccination, partially or totally.
This explanation was criticised by Hart26 as being
inadequate to explain all the differences between the
various BCG vaccine trials. Comstock et al27 also could
not find any evidence for lowered protection by BCG
in the 1980s, Rook, Stanford and associates28-30
proposed that exposure to non-tuberculous mycobacte-
ria (NTM) can result in two types of cell-mediated
responses, the ‘Listeria type’ and the ‘Koch type’.
Which of these two types of responses is evoked de-
pended, among other factors, on the mycobacterial
species inducing the response and the immunomodulating
cells and the pathway brought into play. They further
r posed that the ‘Listeria type’ of response enhances
th  protective effect of subsequent vaccination with
BCG while the ‘Koch type’ response opposes the pro-
t ctive effect of BCG. Once Koch-like responsiveness
is present, this blocks subsequent recognition of further
species by Listeria-like responses. BCG vaccination of
a person with a pre-existing Koch-like response will
tempor rily boost this response, but completely fail to
reconvert to Listeria-like responsiveness or induce
protection from pathoge  nic challenge. According to
them. this is likely to have been the situation in the
south Indian trial.31,32
Investigations carried out since then have been able
to produce some evidence supporting the hypothesis
that infection with NTM induces a protective response
and does not interfere with the immunity produced by
BCG. Attempts to demonstrate that prior infection with
any of the mycobacteria induced a suppressive effect
against BCG have failed.33-36
The study population in the south Indian BCG trial
was characterised by a very high prevalence of nonspe-
cific sensitivity29. Further, nearly 20 percent of the
NTM obtained from sputum samples of subjects in this
area b longed to the Mycobacterium avium-intracellulare-
scrofulaceum (MAE) complex,38 and a recent study on
the isolation profiles of environmental mycobacteria
present in soil, water and dust samples, and sputum
samples of symptomatics in this area has shown that
isolates belonging to the MAIS complex are predomi-
nant i  water. dust and sputum samples while organisms
of the M.fortuitum complex are predominant in soil
samples.39
The hypothesis that oral immunisation with M.avium
intracellulare complex might induce tolerance which
might interfere with the immune response to subsequent
BCG immunisation was studied at the Tuberculosis
Research Centre (TRC)40 in guineapigs challenged with
M.tuberculosis, and it was found that there was no
interference with the protective immunity induced by
BCG. A later study using intradermal route showed
that while there was no interference with the immunity
due to BCG by prior exposure to NTM on the early
course of challenge infection, modulation could be
taking place during the later course.41
The variation in the efficacy of BCG has also been
attributed to the differences between the BCG prepa-
rations.42,43 Another view is that BCG is more effective
in stopping haematogenous spread of the bacteria as
occurring in primary progressive disease and endog-
enous reactivation versus exogenous reinfections.44 Other
explanations include the genetic or physiological dif-
ferences between the trial populations.
More recently, another explanation for the varying
efficacy of BCG has been proposed based on the ob-
servation that a subgroup of the population may be
actually adversely affected by vaccination.45 Several
trials include in the assessment many subject with weak
initial tuberculin sensitivity, due either to environmen-
tal mycobacterialinfection or to infection with
M. tuberculosis.While it is accepted that vaccine
efficacy may be moderately reduced in the former
subgroup, it has been postulated that the lattar subgroup
may be at risk of reactivation of tuberculosis soon after
vaccination perhaps from focal reactions due to en-
hancement of their weak sensitivity. The low levels of
efficacy in several trials, and the early adverse effect 
in the south Indian trial are broadly consistent with this
hypothesis.
In a search for identifying the correlates of vaccine-
induced protective immunity, more than 70000 subjects
in northern Malawi were skin tested with soluble an-
tigens of the tubercle and leprosy bacilli, and then
followed up for 5 years for tuberculosis and leprosy
incidence. Incidence rate ratios were calculated to compare
subjects with different levels of prior skin test sensi-
tivity.46 It was found that delayed type hyper-sensitivity
to mycobacterial antigens has different implications for
tuberculosisand leprosy: low level hypersensitivity,
probably attributable to environmental mycobacteria,
was associated with protection, but persistent vaccine
associated hypersensitivity o mycobacterial antigens
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was not a correlate of vaccine derived protection against
mycobacterial diseases.
BCG Vaccination and HIV Infection
With regard to BCG vaccination in HIV infected
individuals, there are reports of BCG abscesses in HIV
seropositives and of disseminated infection due to BCG
in at least one case given BCG.47 However, in all these
cases,the infection could be successfully treated.
Since the risks and known consequences ofatural
inf ction with tubercle bacilli are likely to be more
serious than the risks associated with live attentuated
vaccines, the WHO has recommended that all asymptomatic
HIV infected children should receive all standard vac-
ci es both live and inactivated; and those with symp-
toms of AIDS Related Complex (ARC)/AIDS should  
receive all vaccines other than BCG. However,
developing countries like India, where extensive HIV
testing is not possible, the WHO Expert Group has
recommended that all infants should continue to receive
immunisation against all the major preventable dis-
eases.48
There is no evidence that BCG activates HIV in-
fection.49 Further, it has been observed that the inci-
dence of disease due to M.avium intracellulare (MAI)
in AIDS patients varies from region to region and it
has been postulated that this difference is the result of
a protective effect of neonatal BCG vaccination.50 I
the USA, 30 per cent of patients with AIDS develop
MAI disease in contrast to only 10 per cent of AIDS
patients in Sweden.This difference in incidence be-
tween the two countries could be due to BCG vacci- 
nation: most Swedish patients with AIDS would have
received BCG in infancy while those in the USA would
be unvaccinated. This is further supported by the fact
that over 50 per cent of AIDS patients in Netherlands,
wher  BCG vaccination is not given, developed disease
due to MAI or M.scrofulaceum. Also, in a limited
follow up of HIV infected individuals at the TRC,
Madras, it has been found that while a few HIV infected
individuals developed disease due to M.tuberculosis no
case has been encountered so far with disease due to
MAI (Tuberculosis Research Centre - Unpublished
observations). It has been suggested that MAI disease
in AIDS is not due to direct infection hut that it arises
from long standing silent foci of MAI in the lymphatic
tissue of the patient.51 I  is possible that  neonatal BCG‘
vaccination prevents overtinfection by MAI and may
therefore prevent inapparent persisting infection of
lymphoid tissue thus removing the internal reservoir of
these bacilli from which AIDS-related MAI disease
may arise later in life.52
BCG as an Immunopotentiating Agent
The widespread use of BCG has demonstrated its
safety and its potent immunogenicity. This has also
led to its suggested use as a carrier to vaccinate against
other diseases.53,54 BCG and other mycobacteria are
highly effective adjuvants. It is one of the few
vaccines that can be given at birth, and with a single
dose it induces long-lived immune responses. Till now,
nearly 3 billion vaccinations have been carried out
using BCG with a long record of safe use in man. There
is also a worldwide distribution network with experi-
ence in BCG vaccination. The adjuvant properties of
BCG and its cell wall components have previously been
made use of in experimental vaccines.Mixtures of
BCG and schistosomal antigens have been used success-
fully to protect mice in a model of schistosomiasis.55
Mixture of muramyl dipeptide, which is one of the
mycobacterial cell wall components that contributes to
the adjuvant properties, and killed simian immunodefi-
ciency virus (SIV) has been shown to provide partial
protection against SIV infection in monkeys.56 Mix-
tures of BCG and killed M.leprae have been used in
large scale trials to assess the efficacy of this leprosy
vaccine candidate.“’
Recombinant BCG and BCG as a Multiple Vaccine
Vehicle
Recently developed genetic engineering techniques
for mycobacteria have provided the means for the
introduction and expression of foreign genes in BCG.53,58
Recombinant BCG vaccine vehicles can induce immune
responses to foreign proteins produced by the bacillus,
indicating that BCG can act simultaneously as an ad-
juvant and as a vehicle to produce and deliver specific
antigens to the immune system. A BCG recombinant
may provide a longer lasting immunity to a pathogen
than a simple mixture of BCG and the antigen because
the antigen continues to be produced by BCG multi-
plying in the host.
There is noready answer for the question whether
there is an alternative for BCG vaccine for protection
against tuberculosis.It is possible to improve the
protective efficacy of the existing BCG vaccine against
tuberculosis by using the tools of genetic engineering
even though very little has been achieved in this di-
rection to date. Such an approach requires a full
understanding of the factors important in the virulence
of M.tuberculoosis, pathogenesis of tuberculosis, and
protective response against tuberculosis. Genetic de-
letion r modification of mycobacterial virulence fac-
tors or the addition of appropriate mycobacterial an-
tig ns important for protection might improve the ef-
fectiveness of BCG as an antitubertulosis vaccine.
Fin  and Rodrigues7 state that several factors, es-
pecially the differences in BCG strains and regional
differences in mycobacterial ecology, in addition to
differ ces in trial methods, have all contributed to the
observed variation in BCG’s efficacy. They conclude
that despite our inability to predict its precise effect.
BCG is still judged worthwhile in many countries
because there is a possibility that the vaccine might
provide reasonable levels of protection against child-
ho  orms of the disease in most populations.7 Recent
ret ospective studies of BCG vaccine efficacy among
newborns and children have reported a protective 
effect against all forms of tuberculosis ranging from 17
to 90 per cent, and protection against tuberculous
meningitis and against cavitary, miliary and bone and
joint tuberculosis has been estimated to be 75 per cent
or greater.59-61 BCG vaccine, when effective, apparently
does not prevent infection hut interferes with the
haematogenous spread of tubercle bacilli, thus reducing
the risk of severe primary disease and its compli-
cations.60 A meta-analysis of 14 trials and 12 case-
control studies showed that the protective effect of BCG
agai st tuberculosis was 51 and 50 per cent respec-
tively.62 Combining data from 7 trials reporting on
deaths from tuberculosis, the relative risk for death
among the vaccinated was 0.29 (7 1% protective effect).
Five case-control studies reporting on tuberculous
meningitis showed a 63 per cent protective effect, and
3 se-control studies reporting efficacy of BCG in
prev .enting disseminated tuberculosis showed a 78 per
cent protective effect.The conclusion was that BCG
reduces the risk for active tuberculosis on an average
by 50 per cent, and therisk for tuberculosis death.
men ngitis and disseminated tubrculosis.The fact that
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continued for children when its use is justified for
prevention.64 BCG vaccination of the newborn usually
protects againstserious forms of tuberculosis is safe
and cheap and should be used in developing countries,
including India, where tuberculosis is more prevalent.
In such highly endemic areas, due to the frequent
occurrence of exogenous reinfection and also due to the
waning of protective effect over the years after vacci-
nation, BCG vaccination of the newborn may not offer
protection in the later years of life when revaccination,
perhaps at the school going age, may have to be
considered. In developed countries with low preva-
lence of tuberculosis, BCG should be given to high risk
groups such as immigrants, their newborn, contacts of
patients with tuberculosis and hospital staff.65
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ABSTRACTS
Some Research Projects Completed Recently
Study of delayed type sensitivity in enteric fever
using outer membraneproteins of Salmonella typhi
as the eliciting antigens:
Immune response specific to outer membrane pro-
teins (OMPs) ofSalmonella typhi was studied in vitro
in 30 bacteriologically proven patients of typhoid in the
acute phase and at follow-up after 3 months.Fifteen
normal healthy controls matched for age and sex and
ther than S. typhi were also
studied. Cell mediated immunity (CMI) against S.
typhi was studied by leucocyte migration inhibition test
(LMIT). Lymphocyte transformation test (LTT), and
  production of interleukin-1 (1L- l a ) and IL-2, and
leukotriene B4 and C4 (LTB4 and LTC4). Enumeration
peripheral lymphocyte sub-
using fluorescein-isothiocyanate
It was observed that S. yphi nduced specific CMI
response in typhoid, both in the acute phase and on
follow up.Of the various in vitro parameters of CMI.
LMIT showed significant inhibition response to OMPs
of S.typhi compared to OMPs of S. typhimurium.The
inhibition was more significant to OMP of S. typhi in
40
